


## Montenegro

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map



| Change since previous survey: ▲ Improvement ▼ Decline |  | 2009   |          | 2012    |          | 2015      |          | 2018      |
|---|--|--------|----------|---------|----------|-----------|----------|-----------|
| International units                                   | Factor VIII  | 0.00   | <b>A</b> | 1.54    | _        | 1.54      | <b>A</b> | 2.02      |
| per capita  | Factor IX  | 0.00   | <b>A</b> | 0.16    | •        | 0.16      | <b>A</b> | 0.29      |
| Organisation  | Comprehensive Care Centres (CCC's)                       | No     |          | No      |          | No        |          | No        |
| of care   | Haemophilia Treatment Centres                            | No     |          | No      |          | No        |          | No        |
|   | National Haemophilia Council or Co-ordinating Group      |        |          |         |          | Yes       | •        | No        |
|   | Number of groups in decision-making on haemophilia care  | 0      |          | 0       | <b>A</b> | 2         |          | 2         |
|   | Number of groups choosing haemophilia treatment products | 0      |          | 0       | <b>A</b> | 1         | <b>A</b> | 2         |
|   | National Tender for procurement of factor concentrates   |        |          |         |          | Yes       |          | Yes       |
| Treatment   | Home Treatment   | No     |          | No      |          | No        | <b>A</b> | Yes       |
| regimens  | % of people with haemophilia using home treatment        | <10%   |          | <10%    |          | <10%      |          | 51-75%    |
|   | Treatment delivered to the patient's home                | No     |          | No      |          | No        |          | No        |
|   | Prophylaxis treatment availability                       |        |          | Some    |          | Some      | <b>A</b> | Yes       |
|   | Children currently on prophy (%)                         |        |          | 76-100% |          | 76-100%   |          | 76-100%   |
|   | Adults currently on prophy (%)                           | 0      |          | 0       |          | 1-25%     | <b>A</b> | 51-75%    |
|   | Access to ITI (% of people with inhibitors)              | 0      |          | 0       |          | 0         |          | 0         |
| Access to   | Emergency medicine and acute surgery                     |        |          |         |          | Yes       |          | Yes       |
| specialist services                                   | Paediatrics  |        |          |         |          | Yes       |          | Yes       |
|   | Infectious disease specialists (especially HIV)          |        |          |         |          | Yes       |          | Yes       |
|   | Hepatology   |        |          |         |          | Sometimes |          | Sometimes |
|   | Rheumatology   |        |          |         |          | Sometimes |          | Sometimes |
|   | Orthopaedics   |        |          |         |          | Yes       |          | Yes       |
|   | Physiotherapy  |        |          |         |          | Sometimes |          | Sometimes |
|   | Dentistry  |        |          |         |          | Sometimes |          | Sometimes |
|   | Obstetrics and Gynaecology                               |        |          |         |          | Yes       |          | Yes       |
|   | Genetics   |        |          |         |          | Sometimes |          | Sometimes |
|   | Social and psychological support                         |        |          |         |          | Never     | <b>A</b> | Sometimes |
|   | Pain management  |        |          |         |          | Never     | <b>A</b> | Sometimes |
|   | General surgery  |        |          |         |          | Yes       |          | Yes       |
|   | Urology  |        |          |         |          | Yes       |          | Yes       |
| Share of Expected                                     | Haemophilia A  |        |          |         |          | 61%       | <b>A</b> | 66%       |
| Bleeding Disorder                                     | Haemophilia B  |        |          |         |          | 27%       | •        | 21%       |
| Prevalence  | von Willebrand Disease                                   |        |          |         |          | 0%        | •        | 0%        |
| Haemophilia   | Pasma-derived factor concentrate                         | Always |          | Always  |          | Always    |          | Always    |
| replacement   | Recombinant factor concentrate                           | Never  |          | Never   |          | Never     |          | Never     |
| therapy   | Plasma   |        |          | Never   |          | Never     |          | Never     |
|   | Cryoprecipitate  |        |          | Never   |          | Never     |          | Never     |
| VWD replacement                                       | Plasma-derived factor concentrate                        |        |          |         |          | Rarely    | •        | Never     |
| therapy   | DDAVP  |        |          |         |          | Always    | •        | Rarely    |
|   | Plasma   |        |          |         |          | Never     |          | Never     |
|   | Cryoprecipitate  |        |          |         |          | Never     |          | Never     |